# A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

> **NCT01231516** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 724 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** GSK1349572
- **DRUG:** Raltegravir
- **DRUG:** GSK1349572 Placebo
- **DRUG:** Raltegravir Placebo

## Key facts

- **NCT ID:** NCT01231516
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-26
- **Primary completion:** 2013-02-04
- **Final completion:** 2021-02-02
- **Target enrollment:** 724 (ACTUAL)
- **Last updated:** 2022-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231516, "A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01231516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*